AACR 2024 Most Interesting Abstract Titles
Highlighting some key abstracts to keep your eye on at AACR 2024 this April
Hello reader! Your sponsorship could go right here at the very top of the next Big Pharma Sharma post. A sponsored post is 100% accessible to all subscriber levels and gets your brand, product, or service in front of my audience of BioPharma Industry decision-makers. If you or your company is interested in becoming a Big Pharma Sharma sponsor, please reach out to me here or on my socials. You can learn more about sponsored posts on the Sponsored Posts page (link).
AACR is just around the corner, taking place from April 5th to 10th in San Diego, CA. The conference has lost impact over the years in my eyes, as more and more companies have chosen to eschew debuting curtain-raising clinical data at this conference. The programs are still rich with interesting pre-clinical science and an early-stage clinical data, which can serve as a major pulse check on the march of innovation in treating cancers.
As I’ve done in the past with other oncology conferences, I’ve sifted through the abstracts and pulled out a select group that have caught my attention. The selection below is just based on my review of the abstract titles but does focus exclusively on clinical data. Full text of the abstracts is available for pre-clinical data. Clinical data will become available only on April 5th. One other thing to keep in mind – AACR has a strange way of categorizing their clinical trial in progress abstracts. Sometimes the trial in progress posters/orals have new data, but most of the time they don’t (like a typical trial-in-progress abstract at other conferences). I’ve tried my best to decipher this through just the titles, but please forgive me if something listed below ends up not having any new data in it.
The highlighted abstracts are broken down by key them below with some additional insights peppered through each section.